Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 2Phase 1 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3

Conditions

Lymphoma, T-Cell, Peripheral 2Hodgkin Disease 2Recurrence 1

Interventions

Rituximab 689Cyclophosphamide 615Vincristine 285Etoposide 272Doxorubicin 271Cytarabine 230Prednisone 229Methotrexate 221fludarabine phosphate 189Filgrastim 187Dexamethasone 180fludarabine 176Lenalidomide 165Radiotherapy 128Melphalan 127Peripheral Blood Stem Cell Transplantation 123Busulfan 118Bendamustine Hydrochloride 116Granulocyte Colony-Stimulating Factor 113Bortezomib 112ibrutinib 111Mycophenolic Acid 110venetoclax 106Whole-Body Irradiation 106obinutuzumab 105Tacrolimus 105Gemcitabine 92zanubrutinib 81Specimen Handling 80Cyclosporine 76

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × AFM13 × Lymphoid × Clear all
NCT05883449 2025-08-20

LuminICE-203

Affimed GmbH

Phase 2 Terminated
25 enrolled 21 charts
Lymphoid

Hodgkin Disease, Recurrence, Lymphoma, T-Cell, Peripheral

NCT04101331 2024-11-05

REDIRECT

Affimed GmbH

Phase 2 Completed
108 enrolled 24 charts
Lymphoid

Lymphoma, T-Cell, Peripheral

NCT02321592 2020-11-13

GHSG-AFM13

University of Cologne

Phase 2 Completed
23 enrolled
Lymphoid

Hodgkin Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡